CD274 and cancer: Since PD-L1 involves many diseases including cancers (i.e., oral cancers) and immune diseases (Gianchecchi et al., 2013; Dai et al., 2014; Roemer et al., 2016), the protocol established in current study may provide a platform for easy and rapid assay of PD-L1 in variety of applications.